Healthcare Industry News: psoriasis
News Release - November 2, 2007
NexMed Appoints Hem Pandya as Chief Operating Officer
EAST WINDSOR, N.J.--(HSMN NewsFeed)--NexMed, Inc. (Nasdaq: NEXM ), a developer of innovative products based on its proprietary NexACT® drug delivery technology, today announced that, effective October 31, 2007, Hem Pandya has joined the Company in the newly created position of Chief Operating Officer. Mr. Pandya will report directly to Chief Executive Officer, Vivian Liu.Commenting on today’s news, Ms. Liu noted, “We are very pleased to welcome Hem to NexMed’s executive team. With over 12 years of pharmaceutical industry experience in the areas of business development, alliance management, strategic planning, and commercial operations, Hem brings a wide spectrum of operational and business development experience and strong leadership skills. Together we will shape the Company’s longer range business strategies.”
Mr. Pandya most recently served as Chief Commercial Officer for Putney, Inc., a start-up veterinary pharmaceutical company. From August 2005 to December 2006, and prior to its merger with Watson Pharmaceuticals, Inc., Mr. Pandya was Senior Vice President of Business Development and Strategic Alliances for Andrx Pharmaceuticals, Inc., where he managed the licensing and co-development opportunities with strategic global partners. From August 2002 to August 2005, Mr. Pandya served as Vice President of Corporate Development and Commercial Operations for Able Laboratories, Inc. Prior to August 2002, Mr. Pandya served in various senior management positions with Ivax Pharmaceuticals, Inc. and Faulding/Purepac Pharmaceutical Company (subsequently Alpharma, Inc.). He received his Bachelor’s Degree from Rutgers University.
About NexMed
NexMed, Inc. is leveraging its proprietary NexACT® drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NexMed’s novel, onychomycosis treatment, licensed to Novartis, is currently in pivotal Phase 3 trials in the U.S. and Europe. In September 2007, NexMed filed a New Drug Application with the FDA for its alprostadil treatment for erectile dysfunction. NexMed’s pipeline also includes a Phase 2 treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.
Source: NexMed
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
